Curamir Therapeutics, a cancer therapeutics developer exploiting Suny research into microRNA, has made its formal debut with $10m of series A funding.
Curamir Therapeutics, a US-based micro RNA cancer drug developer founded by Delos Capital in parnership with State University of New York (Suny), officially launched on Friday with $10m of series A capital from undisclosed investors.
Curamir hopes to develop cancer treatments that rely on microRNA nucleotides to overcome drug resistance and toxicity risks associated with incumbent alternatives.
Targeting microRNA distinguishes Curamir from oncological developers which have historically targeted the messenger RNA subtype.
MicroRNA has garnered medical attention as a cancer biomarker, and Curamir aims to leverage its insights into the nucleotides – involved with RNA silencing and post-transcription gene expression regulation – as the basis for its molecular engineering platform.
The series A capital will help Curamir progress its development pipeline with a view to commencing clinical testing. Curamir Therapeutics was incubated through a licensing deal between Delos Capital and Suny.
Henry Chen, managing director of Delos Capital, has been appointed chief executive of the business. He said: “Curamir is founded with the vision to extend and improve patients’ lives by the discovery and development of innovative microRNA-based oncology therapeutics.”
“We appreciate the significant contribution and strong support from our scientific co-founders, who bring unparalleled knowledge of microRNA therapeutics and a proven track record of discovering and developing transformative therapies. We look forward to further advancing our microRNA pipeline into clinical studies with the series A financing.”
